The second new drug application for the combination of Xindilimumab and Fruquintinib has been accepted by the National Medical Products Administration

June 6, 2025  Source: drugdu 98

 

On June 5th, Xinda Biotechnology and Hehuang Pharmaceutical jointly announced that the new drug application for the combination therapy of Xindilimumab and Fruquintinib for the treatment of locally advanced or metastatic renal cell carcinoma patients who have previously failed treatment with a tyrosine kinase inhibitor has been accepted by the National Medical Products Administration (NMPA) of China. It is reported that the combination therapy of xindilimab and furosemide obtained conditional approval from NMPA in December 2024 for the treatment of advanced mismatch repair intact (pMMR) endometrial cancer patients who have failed previous systemic anti-tumor therapy and are not suitable for radical surgery or radiotherapy.

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.